Arcera Life Sciences

Privately held: no public share price · United Arab Emirates

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
SGLT2Small molecule
Type 2 DiabetesChronic Kidney Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Enavogliflozin · EnvloPhase 3T2DM (Type 2 Diabetes Mellitus)
Est. primary completion 2027-11 · NCT07619833 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.